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Abstract: 
Haplotype-tagging SNP analyses were conducted to identify molecular genetic substrates of 
quantitative phenotypes derived from performance on a Continuous Performance Task (CPT). 
Three hundred sixty-four individuals were sampled from 152 families ascertained on the basis of 
at least one child having ADHD. Probands, their affected and unaffected siblings, and parents 
were administered a CPT. Four different components of performance were analyzed and tested 
for association with SNPs from 10 candidate genes involved in monoaminergic function. After 
correcting for multiple comparisons and controlling for multiple individuals from the same 
family, significant associations were identified between commission errors and SNPs in the 
DRD2 gene (rs2075654, rs1079596), and between reaction time variability and a SNP in the 
NET gene (rs3785155). These findings suggest that commission errors and reaction time 
variability are excellent candidates as ADHD endophenotypes based on previously published 
criteria. Results also shed light on the molecular genetic basis of specific processes that may 
underlie the disorder. 
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INTRODUCTION 
Considerable effort has been devoted to the identification of the molecular genetic basis of 
Attention Deficit Hyperactivity Disorder (ADHD), which is one of the most commonly 
diagnosed psychiatric disorders in children and adults [Goldman et al., 1998; Faraone et al., 
2005; Waldman and Gizer, 2006]. The majority of molecular genetic studies to date, however, 
have only demonstrated small main effects for a range of candidate genes, most of which are 
associated with neurotransmission in monoamine systems (e.g., dopamine, norepinephrine, 
serotonin) [Faraone et al., 2005; Waldman and Gizer, 2006]. It has been argued that the 
variability observed across molecular genetic studies of ADHD is based, in part, on the 
phenotypic heterogeneity that is part of the clinical condition [Buitelaar, 2005; Thapar et al., 
2006]. 
More recently, emphasis has been placed on the identification of sub-phenotypes or 
endophenotypes of ADHD that may help address the problem of phenotypic heterogeneity 
[Hudziak, 2001; Castellanos and Tannock, 2002; Doyle et al., 2005a,b]. In a seminal article, 
Castellanos and Tannock 2002 delineated the essential features of an ADHD endophenotype that 
would increase the likelihood of identifying stronger associations between genetic factors and 
endophenotypic expression. Specifically, they noted that an endophenotype should be 
continuously quantifiable, should predict the disorder probabilistically, should be closer to the 
site of primary causative agent than to diagnostic categories, and should be anchored in 
neuroscience. 
An emerging body of research suggests that neuropsychological, neuroanatomical, and 
neurofunctional deficits among ADHD patients may be suitable candidates for endophenotypes 
based on the criteria described by Castellanos and Tannock. Continuous performance tests (CPT) 
are among the most widely used neuropsychological tests in patients with ADHD. These tasks 
usually assess both sustained attention and the ability to inhibit responding under some 
conditions. In a typical task, a respondent is instructed to attend to a series of target stimuli and 
to make a response (a mouse click or key press, for example) as quickly as possible following 
target stimuli. On some proportion of trials however, a non-target stimulus is presented and the 
respondent is instructed to withhold responding. Performance on CPTs therefore yields a number 
of different measures that are believed to represent different aspects of executive functioning. 
Errors of omission, or not responding to a target stimulus, are believed to index sustained 
attention. Errors of commission, or responding to a non-target stimulus, index response 
inhibition. Other aspects of performance include reaction time and reaction time variability, 
which are believed to index attentional regulation [Castellanos et al., 2005; Sonuga-Barke and 
Castellanos, 2007]. 
CPTs have been widely used to differentiate patients with ADHD from those without. Several 
meta-analyses report moderate to large effect sizes for different aspects of CPT performance 
across ADHD and non-ADHD groups [Frazier et al., 2004; Hervey et al., 2004]. CPT 
performance is therefore both distributed continuously (i.e., quantitatively across clinical and 
non-clinical groups) and predicts ADHD probabilistically, meeting several of the criteria for a 
promising endophenotype described by Castellanos and Tannock 2002. 
The genetic basis of processes underlying CPT performance, such as inhibitory control and 
reaction time variability, among ADHD individuals and their families has also been examined, 
with both family-based and twin studies supporting the heritability of these processes [Nigg et 
al., 2004; Kuntsi et al., 2005]. The molecular genetic basis of CPT performance as it relates to 
ADHD has also been studied in several studies over the past several years, with work focusing 
primarily on variants of several different dopaminergic genes. 
Errors of commission on CPT tasks have been associated with variation in several different 
genes, including the dopamine D4 receptor DRD4 gene [Manor et al., 2002a; Kieling et al., 
2006], the dopamine transporter gene (DAT1; [Loo et al., 2003]), the dopamine D5 receptor 
DRD5 gene [Manor et al., 2004] and the monoamine oxidase A gene (MAOA, [Manor et al., 
2002b]). Similarly, variants of the same genes have also been associated with response 
variability on CPT performance [Manor et al., 2002a, 2004; Loo et al., 2003; Bellgrove et al., 
2005a,b]. 
It is noteworthy that the findings from these molecular genetic studies of CPT performance in 
ADHD samples have been achieved using relatively small samples from ethnically diverse 
backgrounds (e.g., Irish, American, Israeli, British), suggesting that the effects are robust. 
Since the search for valid neuropsychological endophenotypes of ADHD is still nascent, there 
are potential limitations to the above studies that may help guide the refinement of subsequent 
empirical work. Most notably, the majority of previous molecular genetic studies of CPT 
performance have focused primarily on a comparatively limited number of variable-number-of-
tandem-repeat (VNTR) polymorphisms in a handful of genes. One exception to this paradigm 
was a study that found overall CPT performance and response variability influenced by a single 
nucleotide polymorphism (SNP) in the DRD4 gene [Bellgrove et al., 2005b]. Genetic analyses 
using more contemporary haplotype-tagging SNP approaches allow for a more complete 
examination of how variation in specific genes may be associated with specific phenotypes. 
Rather than focusing on a single, repetitive polymorphism within a gene, one examines multiple, 
independent SNPs across the gene. 
The purpose of the present study, therefore, was to examine the molecular genetic associations 
between specific candidate genes and CPT performance using a haplotype-tagging SNP 
approach. We also expanded our examination of candidate genes to study other genes involved 
in monoamine neurotransmission. To this end, we concentrated on the following 10 genes: 
dopamine D1 receptor (DRD1), dopamine D2 receptor (DRD2), dopamine D3 receptor DRD3, 
DRD4, DAT1, serotonin 1B (HTR1B), serotonin transporter (SLC6A4), norepinephrine 
transporter (NET), dopamine beta hydroxylase (DBH), and synaptosomal associated protein 
(SNAP-25). 
METHODS 
Subjects 
Statistical analyses were performed on a total of 364 individuals from 152 families ascertained 
on the basis of at least one child between the ages of 5 and 12 years who met research criteria for 
ADHD. Sixty-nine families contained a single affected child with no other known family history 
of ADHD. The remaining 83 families were comprised of an affected child with additional 
confirmed or suspected family history of ADHD. Mean age of participating children was 9.27 
years (SD = 2.78 years) and mean age of participating parents was 41.11 years (SD = 9.32 years). 
Further details regarding demographics and baseline characteristics of the analyzed sample are 
presented in Table I. Data were collected at two academic sites (Duke University Medical Center 
and University at North Carolina Greensboro), which are both located in central North Carolina. 
Affected individuals and family members provided written informed consent, per study protocols 
approved by the respective institutional review boards (IRBs). 
Table I. Sample Characteristics 
   N/mean %/SD 
Probands/affected Sibs (**includes possibly affected)   180 49.5% 
 ADHD subtype 
  Combined   84 46.7% 
  Hyperactive   20 11.1% 
  Inattentive   67 37.2% 
  Possibly affected   9 5.0% 
 CPRS ADHD index N = 178 74.8 10.3% 
 CTRS ADHD index N = 167 65.3 12.4% 
 Race 
  Non-Hispanic White   143 79.4% 
  Non-Hispanic African-American   29 16.1% 
  Asian-American   3 1.7% 
  Hispanic White   4 2.2% 
  Hispanic Black   1 0.6% 
 Gender 
  Male   125 69.4% 
  Female   55 30.6% 
 FSIQ estimate N = 179 106.7 15.2% 
Affected parent   41 11.3% 
 ADHD subtype 
  Combined   15 36.6% 
  Hyperactive   8 19.5% 
  Inattentive   18 43.9% 
  NOS   0 0.0% 
 CPRS ADHD index   N/A   
 CTRS ADHD index   N/A   
 Race 
  Non-Hispanic White   32 78.1% 
  Non-Hispanic African-American   9 22.0% 
  Asian-American   0 0.0% 
 Gender 
  Male   14 34.2% 
  Female   27 65.9% 
Unaffected/uncertain child   50 13.7% 
   N/mean %/SD 
 Affection status       
  Unaffected   47 94.0% 
  Uncertain   3 6.0% 
 CPRS ADHD index N = 46 52.7 10.4% 
 CTRS ADHD index N = 14 54.2 14.3% 
 Race 
  Non-Hispanic White   44 88.0% 
  Non-Hispanic African-American   3 6.0% 
  Asian-American   0 0.0% 
  Hispanic White   2 4.0% 
  Hispanic Black   1 2.0% 
 Gender 
  Male   25 50.0% 
  Female   25 50.0% 
 FSIQ estimate N = 49 108.7 13.6% 
Unaffected/uncertain parent   93 25.6% 
 Affection status 
  Unaffected   88 94.6% 
  Uncertain   5 5.4% 
 CPRS ADHD index   N/A   
 CTRS ADHD index   N/A   
 Race 
  Non-Hispanic White   76 81.7% 
  Non-Hispanic African-American   15 16.1% 
  Asian-American   0 0.0% 
  Hispanic White   2 2.2% 
  American-Indian   0 0.0% 
 Gender 
  Male   33 35.5% 
  Female   60 64.5%  
 
All children in the family were given a standard assessment battery which included parent 
diagnostic interviews [Shaffer et al., 2000], parent and teacher versions of the Conners' Rating 
Scales to assess cross-situational symptom presentation and developmental deviance of ADHD 
symptoms [Conners, 1997], performance tasks (continuous performance task [CPT; see below]) 
and a brief cognitive screening (a short form of the Wechsler Intelligence Scale to estimate Full 
Scale IQ [FSIQ]). Adults also completed the Conners' Adult ADHD Rating Scale and the CPT. 
Data from all cases, including diagnostic interview results, rating scale results, IQ and CPT 
performance, were reviewed by an expert panel to determine final diagnoses, based on DSM-IV 
criteria. Based on the expert panel review, individuals were classified into one of two categories: 
“affected/possibly affected” and “unaffected/uncertain.” Affected/Possibly Affected individuals 
either met all research criteria for ADHD diagnosis (based on DSM-IV criteria) or met nearly all 
research criteria and the expert panel strongly suspected ADHD given the preponderance of 
evidence from the assessment. Individuals classified as unaffected/uncertain either did not meet 
research criteria for ADHD or had insufficient data to determine affection status. It is relevant 
that this approach to categorizing affection status has been used successfully with other 
psychiatric phenotypes in genetic studies [Yonan et al., 2003]. In addition, CPT data from all 
participants, regardless of affection status, was used for analysis (see below). Comorbidity with 
other psychiatric conditions was not reason for exclusion unless ADHD was not the primary 
diagnosis. Blood was obtained from the affected child, all available siblings and parents under 
IRB-approved procedures. DNA was extracted from whole blood using the Gentra Puregene 
methodology as supplied by Qiagen Inc. (Valencia, California). 
Primary Outcome Measure 
Conners Continuous Performance Test (CPT; [Conners, 2000a]). The Conners continuous 
performance test was completed on an IBM-compatible desktop computer in a quiet setting with 
minimal distractions. Three hundred sixty total letters appeared on the computer screen, one at a 
time, each for approximately 250 msec. The 360 trials were presented in 18 blocks of 20 trials 
each. The blocks differed only in the interstimulus intervals (ISI) between letter presentations, 
which lasted 1-, 2-, or 4-sec. 
Participants were instructed to press the spacebar when any letter except the letter “X” appeared 
on the screen. The percentage of trials when letters other than “X” appeared was 90% across all 
ISI blocks. Given the low rate of “no-go” trials, the task as administered emphasized inhibitory 
control. Reaction time was measured from the point at which any letter other than “X” appeared 
on the screen until the spacebar was pressed. Only successful non-“X” trials, or trials where the 
participant correctly pressed the spacebar when presented with a target stimulus was included for 
reaction time (RT) data analysis. The total Conners' CPT task takes approximately 14 min to 
complete. Six primary outcome variables were derived from CPT performance for the present 
analyses and are described in Table II. For each of the outcome variables, T-scores were used 
since they adjust for age and sex, thus allowing comparability of data from children of all ages 
and adults. The version of the CPT that was used provides normative data for children as young 
as 6 years. A small proportion of our sample (5%) was 5 years of age at the time of testing. For 
these individuals, the 6-year-old norms were used. 
Table II. Description of Measures Analyzed From CPT [From Conners, 2000b] 
Dependent 
measure Description Interpretation measured 
Errors of omission Number of targets (non-X stimuli) that were presented but not responded to 
Sustained attention; higher scores indicate 
lack of orienting to stimuli, or slow, sluggish 
response style 
Errors of 
commission 
Number of non-targets (X-stimuli) that were 
responded to 
Response Inhibition/impulsivity; higher 
scores reflect impulsive or fast response sets 
Hit reaction time Mean response time to all targets 
Fast reaction times with high commission 
errors indicate impulsivity; slow reaction 
times with high omission errors indicate 
inattentionpulsivity 
Hit reaction time 
standard error Variability of hit reaction times 
Refers to erratic nature of responding and 
may represent attentional lapses (see text for 
more details) 
Dependent 
measure Description Interpretation measured 
Detectability (d′) 
Derived from signal detection theory, this index is 
the distance between the signal and noise 
distributions in standard score units; scores index 
the subject's ability to discriminate between targets 
and non-targets 
Sustained attention; higher scores indicate 
better discrimination 
Response style Evaluates speed/accuracy tradeoff 
High scores indicate cautious response style; 
low scores indicate more impulsive response 
style  
 
Genotyping 
SNP genotyping was performed using the Illumina Infinium HumanHap300 duo (Illumina, Inc., 
San Diego, CA). For all genotype assays, quality control measures included genotyping two 
Centre d'Etude du Polymorphism Humain (CEPH) controls for every 94 unique samples. Each 
unique sample was included in the subsequent statistical analysis only if the sample efficiency 
for the entire screen was over 98%. Further, individual markers were excluded if they did not 
achieve over 98% efficiency across all the unique samples. PEDCHECK was used to identify 
and eliminate markers by families due to pedigree inconsistencies [O'Connell and Weeks, 1998]. 
LD Select [Carlson et al., 2004] was used to identify haplotyped-tagging SNPs within our 10 
candidate genes (DRD1, DRD2, DRD3, DRD4, DAT1, HTR1B, SLC6A4, NET, DBH, and 
SNAP-25). Table III lists the location and minor allele frequency for each of the SNPs that were 
assessed. 
Table III. Listing of SNPs Used for Analysis 
Chromosome Gene Probe Base pair location Minor allele frequency 
11 DRD4 HCV1611535 615085 0.33 
11 DRD4 rs35134589 615695 0.25 
11 DRD4 rs3758653 626399 0.18 
11 DRD4 rs936461 626496 0.40 
11 DRD4 7-repeat 629818–630292 0.20 
11 DRD4 rs11246226 631191 0.43 
5 SLC6A3 rs27072 1447522 0.19 
5 SLC6A3 rs40184 1448077 0.49 
5 SLC6A3 rs11133767 1454580 0.34 
5 SLC6A3 rs6869645 1457548 0.09 
5 SLC6A3 rs6347 1464412 0.31 
5 SLC6A3 rs27048 1465645 0.43 
5 SLC6A3 rs37022 1468629 0.21 
Chromosome Gene Probe Base pair location Minor allele frequency 
5 SLC6A3 rs2042449 1469646 0.18 
5 SLC6A3 rs37020 1471374 0.48 
5 SLC6A3 rs464049 1476905 0.48 
5 SLC6A3 rs460700 1482969 0.26 
5 SLC6A3 rs11737901 1483616 0.31 
5 SLC6A3 rs409588 1483834 0.27 
5 SLC6A3 rs460000 1485825 0.26 
5 SLC6A3 rs403636 1491354 0.15 
5 SLC6A3 rs2617605 1495521 0.35 
5 SLC6A3 rs6346 1496163 0.02 
5 SLC6A3 rs6350 1496199 0.07 
5   rs3756450 1501148 0.17 
9   rs1076153 135487964 0.20 
9   rs1076150 135488582 0.49 
9 DBH rs2797849 135491762 0.33 
9 DBH rs3025388 135493077 0.18 
9 DBH rs2007153 135493640 0.39 
9 DBH rs2519155 135494419 0.32 
9 DBH rs1108580 135494935 0.46 
9 DBH rs1108581 135495062 0.23 
9 DBH rs2873804 135495465 0.47 
9 DBH rs5320 135497294 0.07 
9 DBH rs5324 135498479 0.02 
9 DBH rs1611123 135498904 0.45 
9 DBH rs1611125 135499133 0.47 
9 DBH rs1541333 135501206 0.46 
9 DBH rs1541332 135501337 0.48 
9 DBH rs2519154 135502096 0.42 
9 DBH rs2797853 135502336 0.28 
9 DBH rs2283123 135505118 0.11 
9 DBH rs2283124 135505151 0.12 
9 DBH rs77905 135507918 0.47 
9 DBH rs2097628 135509523 0.38 
Chromosome Gene Probe Base pair location Minor allele frequency 
9 DBH rs2073833 135510103 0.43 
9 DBH rs2073837 135512749 0.31 
9 DBH rs129882 135513490 0.20 
17 SLC6A4 rs1042173 25549137 0.41 
17 SLC6A4 rs4325622 25550601 0.39 
17 SLC6A4 rs3794808 25555919 0.42 
17 SLC6A4 rs140701 25562658 0.40 
17 SLC6A4 rs140700 25567515 0.07 
17 SLC6A4 rs6354 25574024 0.20 
17 SLC6A4 rs2066713 25575791 0.35 
17 SLC6A4 rs8071667 25576899 0.19 
20   rs6104567 10143433 0.24 
20   rs1889189 10145086 0.31 
20 SNAP25 rs6039769 10146954 0.29 
20 SNAP25 rs6032826 10151817 0.27 
20 SNAP25 rs3787303 10156748 0.21 
20 SNAP25 rs2423486 10160212 0.28 
20 SNAP25 rs2423487 10161095 0.10 
20 SNAP25 rs363032 10166644 0.10 
20 SNAP25 rs363039 10168496 0.35 
20 SNAP25 rs363043 10174146 0.31 
20 SNAP25 rs363016 10179174 0.40 
20 SNAP25 rs363050 10182257 0.37 
20 SNAP25 rs6074113 10190011 0.48 
20 SNAP25 rs362563 10191251 0.07 
20 SNAP25 rs362569 10194733 0.39 
20 SNAP25 rs362584 10202475 0.29 
20 SNAP25 rs6039806 10206654 0.45 
20 SNAP25 rs6077718 10209142 0.12 
20 SNAP25 rs6039807 10211576 0.50 
20 SNAP25 rs2284297 10213897 0.05 
20 SNAP25 rs362549 10217890 0.45 
20 SNAP25 rs6108463 10228505 0.24 
Chromosome Gene Probe Base pair location Minor allele frequency 
20 SNAP25 rs362988 10229370 0.47 
20 SNAP25 rs4813925 10234313 0.36 
20 SNAP25 rs1051312 10235088 0.45 
20 SNAP25 rs362552 10244217 0.37 
11 DRD2 rs2242592 112784640 0.40 
11 DRD2 rs6279 112786283 0.38 
11 DRD2 rs6277 112788669 0.47 
11 DRD2 rs2075654 112794276 0.13 
11 DRD2 rs2587548 112797422 0.46 
11 DRD2 rs1076563 112801119 0.47 
11 DRD2 rs1079596 112801829 0.14 
11 DRD2 rs2471857 112803549 0.14 
11 DRD2 rs4586205 112812339 0.34 
11 DRD2 rs4620755 112814829 0.14 
11 DRD2 rs7125415 112815891 0.11 
11 DRD2 rs4648318 112818599 0.32 
11 DRD2 rs17601612 112822955 0.32 
11 DRD2 rs4274224 112824662 0.49 
11 DRD2 rs4581480 112829684 0.15 
11 DRD2 rs7131056 112834984 0.49 
11 DRD2 rs4350392 112840927 0.14 
11 DRD2 rs4938019 112846601 0.14 
11 DRD2 rs12364283 112852165 0.06 
5 DRD1 rs4867798 174800505 0.29 
5 DRD1 rs4532 174802756 0.34 
5 DRD1 rs5326 174802802 0.13 
6 HTR1B rs13212041 78227843 0.24 
6 HTR1B rs6298 78229711 0.27 
3 DRD3 rs2134655 115340891 0.25 
3 DRD3 rs963468 115345577 0.38 
3 DRD3 rs3773678 115352768 0.19 
3 DRD3 rs2630351 115357749 0.06 
3 DRD3 rs167771 115358965 0.23 
Chromosome Gene Probe Base pair location Minor allele frequency 
3 DRD3 rs167770 115362252 0.30 
3 DRD3 rs226082 115363703 0.30 
3 DRD3 rs324029 115364313 0.30 
3 DRD3 rs10934256 115368342 0.19 
3 DRD3 rs1486009 115371222 0.04 
3 DRD3 rs6280 115373505 0.35 
3   rs9825563 115382910 0.33 
16 SLC6A2 rs2242446 54247926 0.25 
16 SLC6A2 rs36030 54250791 0.16 
16 SLC6A2 rs17307096 54251784 0.34 
16 SLC6A2 rs3785143 54252607 0.07 
16 SLC6A2 rs192303 54257725 0.34 
16 SLC6A2 rs41154 54260207 0.39 
16 SLC6A2 rs36024 54263892 0.42 
16 SLC6A2 rs187714 54264000 0.38 
16 SLC6A2 rs36023 54264755 0.42 
16 SLC6A2 rs36021 54269451 0.43 
16 SLC6A2 rs3785152 54274051 0.08 
16 SLC6A2 rs40147 54274341 0.29 
16 SLC6A2 rs1814269 54274529 0.42 
16 SLC6A2 rs36016 54277535 0.47 
16 SLC6A2 rs3785155 54279891 0.15 
16 SLC6A2 rs880711 54280882 0.18 
16 SLC6A2 rs11862589 54281443 0.49 
16 SLC6A2 rs879519 54281912 0.50 
16 SLC6A2 rs5568 54287625 0.34 
16 SLC6A2 rs1566652 54289076 0.36 
16 SLC6A2 rs36010 54289169 0.04 
16 SLC6A2 rs5569 54289336 0.27 
16 SLC6A2 rs36009 54290121 0.08 
16 SLC6A2 rs42460 54295157 0.08 
16   rs10521330 54297655 0.20 
 
 
Statistical Analysis 
Hardy–Weinberg equilibrium was assessed using exact tests implemented in the Genetic Data 
Analysis program [Zaykin et al., 1995]. Pairwise linkage disequilibrium (D′ and r2) between 
markers within each gene was calculated using the software package GOLD [Abecasis and 
Cookson, 2000]. All analyses were conducted using programs specifically designed for family 
data, to account for the dependency among relatives. As described above, several quantitative 
phenotypes from the CPT were examined for both genetic association and linkage with our SNP 
data. One of the requirements for these analyses was that the trait under investigation be 
normally distributed. Several transformations were tested for CPT omission errors and response 
style, but none produced a normal distribution of these phenotypes, largely because of 
distributional skewness. These variables were subsequently removed from analysis. The 
remaining CPT phenotypes (commission errors, hit reaction time, hit reaction time standard 
error, and detectability) did not significantly deviate from a normal distribution and were used 
without transformation in all analyses. 
Pearson correlations were calculated for each pairwise combination of the CPT variables. The 
association between CPT variables and affection status was evaluated using Generalized 
Estimating Equations (GEE) with the PROC GENMOD procedure in SAS version 9.1. The GEE 
approach controls for familial correlation among individuals from the same family. Further, we 
examined the association between the SNPs and affection status using the association in the 
presence of linkage (APL) test. APL provides a novel test for association in the presence of 
linkage that also correctly infers missing parental genotypes by estimating identity-by-descent 
parameters (IBD) [Chung et al., 2006]. 
The heritabilities of CPT phenotypes were assessed in our data set using Sequential Oligogenic 
Linkage Analysis Routines (SOLAR) [Almasy and Blangero, 1998]. The “polygenic” command 
in SOLAR was used to obtain heritabilities. This analysis uses familial data to estimate how 
much of the variance in a quantitative phenotype is due to heritable factors. The QTDT 
[Abecasis et al., 2000a,b] and SOLAR were used to test for the presence of genetic association 
and genetic linkage, respectively. 
For the QTDT, we present the Monks–Kaplan exact test because it is a conservative TDT-like 
method for families with multiple siblings with or without parents. The exact test version of 
Monks–Kaplan was used because of the small sample size of our data set. We accounted for 
possible false-positive associations due to multiple testing by adjusting the nominal P-values 
using the false discovery rate (FDR) procedure developed by Benjamini and Hochberg 1995 and 
chose a threshold of 0.10 for declaring significance. The concept of the FDR was proposed to 
relax the stringent property of Bonferroni correction. As originally proposed, the FDR first ranks 
all P-values from high to low (P(N) > P(N−1) > … > P(1)). Each P-value is then compared to 
(i × 0.05)/N, where i is the rank of the observed P-value and N is the total number of SNPs. 
When P(j) < 0.05/j is significant, SNPs ranked below P(j) are also declared to be significant. 
With the threshold set at 0.10, on average, 10% of associations identified by this procedure as 
significant will be false-positive discoveries. We calculated the FDR q-values using PROC 
MULTTEST in SAS version 9.1. 
RESULTS 
The Pearson correlations amongst the four CPT phenotypes generally were high and statistically 
significant, with the exception of the correlations between commission errors and hit reaction 
time standard error (r = 0.01; P = 0.91), and between hit reaction time standard error, and 
detectability (r = −0.02, P = 0.64), suggesting that these performance parameters measured 
independent processes. 
The heritabilities of the CPT phenotypes are shown in Table IV. Age was tested as a covariate in 
all four estimates of heritability, but was not significantly associated with any of the phenotypes. 
Thus, reported heritability estimates are without including age as a covariate. It is important to 
note that since age-adjusted T-scores were used for analyses, the lack of age effects was not 
unexpected. Estimates of heritability for the four significant phenotypes fell between 28% and 
57%, which is generally considered to be reasonably heritable for genetic analysis of a 
quantitative trait. 
Table IV. Heritability Estimates for CPT Parameters 
Outcome Heritability estimate P-value 
Commission errors 0.4273 0.0002 
Hit Reaction time 0.5682 0.0000 
Hit Reaction time Standard error 0.2827 0.0068 
Detectability 0.3154 0.0043 
 
Descriptive data for CPT and results from the analysis predicting affection status from these 
variables are included in Table V. Commission errors were significantly associated with 
affection status (P = 0.04), but the other CPT parameters failed to reach statistical significance 
although there were several trends in the expected direction (P-values for hit reaction time, 
reaction time standard error, and variability, were all at or below P = 0.10). A number of SNPs 
from SNAP-25, DBH, NET, SLC6A4, DRD3, and DRD4 were nominally associated with 
affection status in this sample (data not shown, P's = 0.01–0.04), but none withstood multiple 
testing corrections. 
Table V. Means and SDs for CPT Parameters in Affected and Unaffected Individuals 
Outcome Mean (SD) P-value for parameter predicting affection statusa 
 
Commission errors   0.04 
 Affected 50.86 (11.84)   
 Unaffected 48.27 (9.46)   
Hit reaction time   0.10 
 Affected 52.38 (11.93)   
 Unaffected 50.27 (11.62)   
Hit reaction time standard error   0.10 
 Affected 53.70 (10.61)   
 Unaffected 51.77 (11.32)   
Variability   0.07 
 Affected 52.72 (11.33)   
 Unaffected 50.61 (10.60)   
Detectability   0.24 
 Affected 50.77 (11.33)   
 Unaffected 49.42 (10.25)   
a Based on APL analysis (see text). 
Significant results of the QTDT analysis for genetic association with the CPT phenotypes are 
shown in Table VI. Commission errors were significantly associated with SNPs in two of the 
genes (DRD3 and DRD2), although only the associations with DRD2 SNPs (rs2075654 and 
rs1079596) remained significant after applying the FDR correction. 
Table VI. Results From QTDT Analyses 
Gene SNP CPT outcome Uncorrected P-value FDR q-value 
SLC6A3 (DAT1) rs37020 HRTSE 0.008 0.352 
  rs464049 HRTSE 0.031 0.8184 
  rs409588 HRTSE 0.041 0.891 
  rs2042449 Detectability 0.049 0.98 
DBH rs1611125 Detectability 0.049 0.98 
  rs77905 Detectability 0.047 0.98 
SNAP-25 rs6104567 HRT 0.007 0.924 
  rs363016 HRT 0.041 0.99 
  rs6104567 HRTSE 0.015 0.49 
DRD2 rs2075654 Commission <0.0001 0.0132 
  rs1079596 Commission 0.001 0.066 
  rs2471857 Commission 0.003 0.132 
  rs7131056 Commission 0.025 0.825 
  rs7125415 Detectability 0.006 0.792 
DRD3 rs3773678 Commission 0.043 0.97 
Gene SNP CPT outcome Uncorrected P-value FDR q-value 
  rs3773678 HRT 0.042 0.99 
  rs3773678 Detectability 0.045 0.98 
SLC6A2 (NET) rs3785155 HRTSE <0.0001 0.0132 
  rs880711 HRTSE 0.004 0.264 
 
 
Hit reaction time standard error showed significant associations with SNPs in the DAT1, SNAP-
25, and NET genes. Only one SNP in the NET gene (rs3785155) remained significant after 
correcting for FDR. Detectability was significantly associated with SNPs in the DAT1, DBH, 
DRD2, and DRD3 genes, although the magnitude of these associations was generally lower that 
those observed for commission errors and hit reaction time standard error, and none of the 
associations remained significant at the FDR threshold (q < 0.10). Similarly, hit reaction time 
was associated with SNPs in the SNAP-25 and DRD3 genes, but these associations were less 
robust and did not withstand corrections for multiple comparisons. 
DISCUSSION 
The present study found nominally significant associations between parameters of CPT 
performance and SNPs in six different genes associated with monoamine function: DRD2, 
DRD3, DAT1, DBH, NET, and SNAP-25. After correcting for multiple comparisons, however, 
only SNPs in the DRD2 and NET genes were significantly associated with commission errors 
and hit reaction time standard error, respectively. 
Two of the genes we examined in this study, DRD4 and DAT1 have been associated with 
aspects of CPT performance in previous studies [Manor et al., 2002a; Loo et al., 2003; Bellgrove 
et al., 2005b; Kieling et al., 2006]. We found no associations with any SNPs in the DRD4 gene 
and although several associations between hit reaction time standard error were nominally 
associated with DAT1 SNPs, these failed to withstand corrections for multiple testing. We 
specifically examined the DRD4 7-repeat allele given its strong previous association with CPT 
phenotypes [Manor et al., 2002a; Langley et al., 2004; Kieling et al., 2006]. However, this 
marker was not associated with any of the quantitative phenotypes that we examined. 
One possible reason that we did not replicate these previous findings was that the composition of 
our sample differed. Without exception, previous studies that have investigated the molecular 
genetics of performance-based phenotypes using the CPT and other similar tasks have used only 
clinical samples that were usually stratified on the basis of single risk alleles (e.g., the 7-repeat 
allele of the DRD4, or the 10-repeat of the DAT1). Our approach was different in that we 
analyzed data from both ADHD probands and their affected and unaffected siblings, as well as 
parents who also varied with respect to their ADHD presentation. 
Compared to most previous studies that have examined the molecular genetic basis of CPT 
performance, our sample was considerably larger, affording more statistical power to identify 
meaningful genotype-phenotype relationships. Our findings are consistent with a number of 
studies that have shown both reaction time variability (indexed in this study by hit reaction time 
standard error) and commission errors as being among the most sensitive cognitive measures to 
discriminate ADHD from non-ADHD samples [Frazier et al., 2004; Hervey et al., 2004]. 
Moreover, reaction time variability has also been shown to be heritable in family and twin-based 
studies [Kuntsi et al., 2006]. 
Based on previous recommendations for evaluating candidate endophenotypes [Castellanos and 
Tannock, 2002], the present findings lend strong support for the use of commission errors and 
reaction time variability in future molecular genetic studies of ADHD. As noted these 
phenotypes predict the disorder probabilistically and are continuously quantifiable. We have also 
demonstrated that these phenotypes are heritable. The remaining criteria described by 
Castellanos and Tannock are that the endophenotype should be more proximal to the causative 
agent (i.e., the genotype) than the diagnostic category with which it is associated, and it should 
also be anchored in neuroscience. Regarding the latter, both inhibitory control and intra-subject 
response variability have been shown to have distinct and dissociable neural bases [Aron et al., 
2007; Clare Kelly et al., 2008]. Since specific genes that we have found to be associated with 
inhibitory control and response time variability (DRD2 and NET) are more strongly associated 
with the candidate endophenotypes than the disorder itself, the former criterion regarding 
proximity to causal agents is also met. 
The specific associations observed in the present study are also consistent with other work 
linking the endophenotypes, candidate genes, and monoaminergic dysfunction. Both 
norepinephrine and dopamine activity have previously been hypothesized to be associated with 
unique aspects of cognitive dysfunction characteristic of ADHD [Viggiano et al., 2004; Pliszka, 
2005]. Variation in the DRD2 gene has been consistently associated with a range of substance 
use disorders, including alcohol abuse/dependence and nicotine dependence [Noble, 1998, 2000; 
Munafo et al., 2004], both of which are more common in individuals diagnosed with ADHD 
[Wilens, 2007]. Moreover, deficits in inhibitory control are thought to be central to the 
development of many substance use disorders [Ivanov et al., 2008]. A recent study also 
demonstrated that individuals with alcohol dependence who carried the TaqIA polymorphism of 
the DRD2 gene exhibited poorer inhibitory control on a CPT [Rodriguez-Jimenez et al., 2006]. 
Our group also reported that DRD2 genotype interacts with self-reported symptoms in a 
population based sample of young adults to predict lifetime risk of regular smoking [McClernon 
et al., 2008]. Taken together these findings suggest that DRD2 modulated effects on inhibitory 
control may represent a plausible mechanism for risk of subsequent substance use problems in 
individuals with ADHD. The present findings point to specific regions of the DRD2 gene that 
should be investigated further to evaluate this hypothesis. 
Previous work has also shown that attention and attentional lapses, like those believed to be 
indexed by reaction time variability are largely mediated through noradrenergic pathways, 
suggesting a critical role of the NET receptor in these kinds of processes [Smith and Nutt, 1996]. 
As such, our finding of strong associations between reaction time variability and SNPs on the 
NET receptor gene is consistent with previous neurobiological work. 
At least two limitations to the present study are endemic to the haplotype tagging SNP analysis 
of any complex trait. First, in order to adequately survey the genetic variation across any given 
gene, a large number of SNPs are required. This in turn reduces power to detect effects of small 
size when appropriate statistical corrections are applied. As such, some of our nominally 
significant findings may actually be meaningful, but our FDR correction renders conclusions 
about these associations tenuous. Second, there are some genes for which reasonable SNP 
coverage across the gene was not available. For example, for the DRD4 and HTR1B genes, only 
five and two tagging SNPs were identified, respectively. The consequence of this limitation is 
that rare variations in these genes may be associated with CPT phenotypes, but we did not 
examine SNPs with frequencies less than 0.02 (see Table III). 
Two additional related limitations are worth noting. First, only commission errors from the CPT 
significantly predicted affection status in our data set, although hit reaction time standard error 
trended in the expected direction. Second, we failed to find associations between the SNPs of 
interest (i.e., those associated with commission errors and hit reaction time standard error) and 
affection status. Together, these findings warrant caution in the interpretation of the potential for 
these endpoints as viable endophenotypes for the diagnosis of ADHD. 
In spite of these limitations, our findings are the first to show strong associations that withstand 
FDR corrections between hapolotype tagging SNPs and quantitative CPT endophenotypes. Of 
particular note is that these findings suggest distinct genetic substrates for traits that are 
associated with two of the core features of ADHD: errors of commission (impulsivity) and 
reaction time variability (attention/attentional lapses). Of course, this interpretation is likely to be 
somewhat oversimplified, but the data represent an important incremental next step in linking 
specific genetic variation to quantitative phenotypes that may improve our understanding of 
ADHD. 
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